Orlando, FL 12/20/11 (StreetBeat) -- Bioanalytical Systems, Inc. (NASDAQ: BASI) today announced financial results for the fourth quarter and fiscal year ended September 30, 2011.Fiscal 2011 Results
Net income for fiscal 2011 ended September 30, 2011 increased to $543,000. This compares to a net loss for fiscal 2010 of $2,691,000. Revenue increased 15.2% for fiscal 2011 to $33,144,000 from $28,781,000 for fiscal 2010, and gross margin improved to 31.7% versus 25.5%.
"Fiscal 2011 was BASi's first profitable year since fiscal 2007," said President and Chief Executive Officer Anthony Chilton, "and we are optimistic that the company will deliver further revenue and earnings growth in fiscal 2012."
During fiscal 2011, BASi paid down $1,000,000 of long term debt and closed an oversubscribed public offering for $5,506,000 of units consisting of convertible preferred shares and warrants to purchase common shares. Accounting for the value of the warrants and the preferred shares in the third quarter and first nine months of fiscal 2011 resulted in a one-time deemed dividend to preferred stockholders of $3,277,000, which was deducted from net earnings to compute GAAP earnings per share. Additionally, the Company immediately charged $991,080, the payment-in-kind dividends payable to the preferred stockholders, against net earnings to compute GAAP earnings per share. This resulted in a GAAP loss per share of $0.66 for fiscal 2011, compared to a net loss per share of $0.55 for fiscal 2010.
Excluding the deemed dividend to preferred shareholders and the preferred dividend, diluted net income per share would have been $0.09 for fiscal 2011. Management considers the income available to common shareholders and earnings per share exclusive of the dividends to be a useful measure in evaluating the operating results of BASi. A reconciliation of GAAP to non-GAAP financial measures is provided in the table attached to this press release.
Fourth Quarter Results For the fourth quarter ended September 30, 2011, revenue increased 10.1% to $8,153,000 compared to $7,405,000 for the fourth quarter of fiscal 2010. Primarily due to the mix of services provided and unusually high general and administrative expense, the net loss for the fourth quarter of fiscal 2011 was $668,000, or $0.10 per share, compared to a net loss of $279,000, or $0.06 per share, for the fourth quarter of fiscal 2010.
Balance Sheet Highlights At September 30, 2011, BASi reported cash and cash equivalents of $2,963,000, working capital of $526,000, total long-term obligations of $6,913,000, and shareholders' equity of $15,586,000, or $2.26 per outstanding share. At September 30, 2010, cash and cash equivalents were $1,422,000, the working capital deficiency was $3,342,000, total long-term obligations were $7,100,000, and shareholders' equity was $10,667,000, or $2.17 per outstanding share.
CEO Comments President and CEO Chilton said, "We generated cash and delivered solid revenue growth and substantially improved bottom-line performance in fiscal 2011 despite a difficult economic environment and delays in certain projects. While business conditions remain challenging, well-established trends in our industry clearly indicate that new drug discovery and development will rely increasingly on outsourcing in the years ahead. As a provider of contract research services for more than 35 years, BASi is positioned to take advantage of these trends by expanding our business with the growing population of small biotech and pharmaceutical companies that have become a major force in new drug discovery, even as we enhance our historically close relationships with major pharmaceutical clients.
"We expanded our sales staff and increased selling expenses by 17% in fiscal 2011 versus prior year in support of this growth strategy, which helped us add more than 25 new accounts to our client roster in fiscal 2011. We also are seeking to expand our service offerings through accretive acquisitions if appropriate opportunities become available. We are confident that we are on the right track to deliver further growth and enhance shareholder value."
StreetBeat Disclaimer
No comments:
Post a Comment